Targeting a specific protein to treat certain blood cancers
Targeting GSK3B in refractory B-cell malignancies
This study is looking at how a protein called GSK3B affects another protein, E-catenin, which plays an important role in certain blood cancers like acute lymphoblastic leukemia, and it aims to find new treatments using special drugs that target GSK3B to help patients with these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10890884 on NIH RePORTER |
What this research studies
This research investigates how a protein called GSK3B regulates another protein, E-catenin, which is crucial in the development of B-cell malignancies like acute lymphoblastic leukemia. The study aims to understand the unique interactions between E-catenin and other proteins in B-cell cancers, which differ from solid tumors. By using small molecule inhibitors that target GSK3B, the research seeks to exploit a new therapeutic approach that could lead to effective treatments for patients with these types of blood cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with refractory B-cell malignancies, particularly those who have not responded to standard treatments.
Not a fit: Patients with solid tumors or those without B-cell malignancies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with refractory B-cell malignancies.
How similar studies have performed: Other research has shown promising results using similar approaches to target GSK3B in different cancer types, indicating potential for success in this area as well.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Müschen, Markus — Yale University
- Study coordinator: Müschen, Markus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.